Merck Unit Sues To Block Teva's Generic Singulair

Law360, New York (January 13, 2012, 5:31 PM EST) -- Merck Canada Inc. on Friday sued Teva Pharmaceuticals USA Inc. in New Jersey federal court for allegedly infringing a Merck patent with its request for approval of a generic version of the asthma treatment Singulair.

Merck Canada, Merck Frosst Canada & Co. and Merck Sharp & Dohme Pharmaceuticals say they learned of Teva's plans to market a generic Singulair in a Nov. 29 letter notifying them of Teva's abbreviated new drug application with the U.S. Food and Drug Administration.

In the letter, Teva included a Paragraph...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.